Exagen Net Worth
Exagen Net Worth Breakdown | XGN |
Exagen Net Worth Analysis
Exagen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Exagen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Exagen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Exagen's net worth analysis. One common approach is to calculate Exagen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Exagen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Exagen's net worth. This approach calculates the present value of Exagen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Exagen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Exagen's net worth. This involves comparing Exagen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Exagen's net worth relative to its peers.
Enterprise Value |
|
To determine if Exagen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exagen's net worth research are outlined below:
| Exagen Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 55.64 M. Reported Net Loss for the year was (15.12 M) with profit before taxes, overhead, and interest of 34.98 M. | |
| Exagen Inc has about 76.39 M in cash with (13.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7. | |
| Exagen Inc has a poor financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: Institutional investors have a lot riding on Exagen Inc. with 38 percent ownership |
Exagen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exagen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exagen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Exagen Target Price Consensus
Exagen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Exagen's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Exagen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Exagen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Exagen Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationExagen Target Price Projection
Exagen's current and average target prices are 10.92 and 11.71, respectively. The current price of Exagen is the price at which Exagen Inc is currently trading. On the other hand, Exagen's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Exagen Market Quote on 30th of September 2025
Target Price
Analyst Consensus On Exagen Target Price
Know Exagen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exagen Inc backward and forwards among themselves. Exagen's institutional investor refers to the entity that pools money to purchase Exagen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Acadian Asset Management Llc | 2025-06-30 | 220.6 K | Fourworld Capital Management Llc | 2025-06-30 | 208.5 K | Manatuck Hill Partners Llc | 2025-06-30 | 175 K | Geode Capital Management, Llc | 2025-06-30 | 146.5 K | Point72 Asset Management, L.p. | 2025-06-30 | 136.4 K | Mink Brook Asset Management Llc | 2025-06-30 | 130 K | The Informed Momentum Company (formerly Eam Investors) | 2025-06-30 | 97.8 K | Ameriprise Financial Inc | 2025-06-30 | 95 K | Huntleigh Advisors Inc | 2025-06-30 | 87.9 K | Rtw Investments, Llc | 2025-06-30 | 1.7 M | The Toronto-dominion Bank | 2025-06-30 | 851.3 K |
Follow Exagen's market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 239.62 M.Market Cap |
|
Project Exagen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.58) | (1.66) |
When accessing Exagen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Exagen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exagen's profitability and make more informed investment decisions.
Evaluate Exagen's management efficiency
Exagen Inc has Return on Asset of (0.1624) % which means that on every $100 spent on assets, it lost $0.1624. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.8794) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of September 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.46. At this time, Exagen's Other Assets are very stable compared to the past year. As of the 30th of September 2025, Net Tangible Assets is likely to grow to about 51.3 M, while Return On Tangible Assets are likely to drop (0.36).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.52 | 0.55 | |
| Tangible Book Value Per Share | 0.52 | 0.55 | |
| Enterprise Value Over EBITDA | (6.82) | (7.16) | |
| Price Book Value Ratio | 7.82 | 8.21 | |
| Enterprise Value Multiple | (6.82) | (7.16) | |
| Price Fair Value | 7.82 | 8.21 | |
| Enterprise Value | 76 M | 79.8 M |
At Exagen Inc, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 3.9888 | Revenue | Quarterly Revenue Growth 0.142 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exagen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Exagen Corporate Filings
F4 | 4th of September 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of August 2025 Other Reports | ViewVerify | |
8K | 29th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of June 2025 Other Reports | ViewVerify |
Exagen Earnings Estimation Breakdown
The calculation of Exagen's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Exagen is estimated to be -0.174375 with the future projection ranging from a low of -0.1875 to a high of -0.1625. Please be aware that this consensus of annual earnings estimates for Exagen Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.19 Lowest | Expected EPS | -0.16 Highest |
Exagen Earnings Projection Consensus
Suppose the current estimates of Exagen's value are higher than the current market price of the Exagen stock. In this case, investors may conclude that Exagen is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Exagen's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 8 | 63.23% | 0.0 | -0.174375 | -0.89 |
Exagen Earnings per Share Projection vs Actual
Actual Earning per Share of Exagen refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Exagen Inc predict the company's earnings will be in the future. The higher the earnings per share of Exagen, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Exagen Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Exagen, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Exagen should always be considered in relation to other companies to make a more educated investment decision.Exagen Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Exagen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-07-29 | 2025-06-30 | -0.15 | -0.21 | -0.06 | 40 | ||
2025-05-12 | 2025-03-31 | -0.36 | -0.2 | 0.16 | 44 | ||
2025-03-17 | 2024-12-31 | -0.24 | -0.2 | 0.04 | 16 | ||
2024-11-12 | 2024-09-30 | -0.29 | -0.2754 | 0.0146 | 5 | ||
2024-08-05 | 2024-06-30 | -0.34 | -0.16 | 0.18 | 52 | ||
2024-05-13 | 2024-03-31 | -0.36 | -0.19 | 0.17 | 47 | ||
2024-03-18 | 2023-12-31 | -0.43 | -0.31 | 0.12 | 27 | ||
2023-11-13 | 2023-09-30 | -0.47 | -0.31 | 0.16 | 34 | ||
2023-08-07 | 2023-06-30 | -0.49 | -0.28 | 0.21 | 42 | ||
2023-05-15 | 2023-03-31 | -0.56 | -0.44 | 0.12 | 21 | ||
2023-03-20 | 2022-12-31 | -0.78 | -0.83 | -0.05 | 6 | ||
2022-11-14 | 2022-09-30 | -0.73 | -0.47 | 0.26 | 35 | ||
2022-08-04 | 2022-06-30 | -0.57 | -0.78 | -0.21 | 36 | ||
2022-05-11 | 2022-03-31 | -0.61 | -0.6 | 0.01 | 1 | ||
2022-03-22 | 2021-12-31 | -0.5 | -0.42 | 0.08 | 16 | ||
2021-11-10 | 2021-09-30 | -0.46 | -0.42 | 0.04 | 8 | ||
2021-08-09 | 2021-06-30 | -0.44 | -0.38 | 0.06 | 13 | ||
2021-05-11 | 2021-03-31 | -0.47 | -0.48 | -0.01 | 2 | ||
2021-03-16 | 2020-12-31 | -0.41 | -0.27 | 0.14 | 34 | ||
2020-11-10 | 2020-09-30 | -0.47 | -0.34 | 0.13 | 27 | ||
2020-07-28 | 2020-06-30 | -0.76 | -0.27 | 0.49 | 64 | ||
2020-05-11 | 2020-03-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2020-03-25 | 2019-12-31 | -0.37 | -0.27 | 0.1 | 27 | ||
2019-11-12 | 2019-09-30 | -2.4 | -2.3 | 0.1 | 4 | ||
2019-09-20 | 2019-06-30 | 0 | -1.6 | -1.6 | 0 | ||
2015-05-18 | 2015-03-31 | 0 | -0.27 | -0.27 | 0 |
Exagen Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Debra Zack | Chief Officer | Profile | |
| John Wegener | Senior Marketing | Profile | |
| Ryan Douglas | Investors Officer | Profile | |
| Mark Hazeltine | Chief Officer | Profile | |
| MingChou Lee | Chief Officer | Profile |
Already Invested in Exagen Inc?
The danger of trading Exagen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exagen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exagen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exagen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.142 | Return On Assets | Return On Equity |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.